Total Payments
$83,465
2024 Payments
$4,849
Companies
11
Transactions
73
Medicare Patients
2,351
Medicare Billing
$508,916
Payment Breakdown by Category
Consulting$32,370 (38.8%)
Travel$18,619 (22.3%)
Research$17,398 (20.8%)
Other$13,688 (16.4%)
Food & Beverage$1,376 (1.6%)
Education$15.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $32,370 | 8 | 38.8% |
| Travel and Lodging | $18,619 | 15 | 22.3% |
| Unspecified | $17,398 | 20 | 20.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,688 | 5 | 16.4% |
| Food and Beverage | $1,376 | 24 | 1.6% |
| Education | $15.00 | 1 | 0.0% |
Payments by Type
General
$66,067
53 transactions
Research
$17,398
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Siemens Medical Solutions USA, Inc. | $27,659 | 30 | $0 (2024) |
| Progenics Pharmaceuticals, Inc. | $22,545 | 10 | $0 (2022) |
| Y-mAbs Therapeutics, Inc. | $17,398 | 20 | $0 (2024) |
| Ipsen Bioscience Inc | $8,000 | 1 | $0 (2020) |
| Bayer HealthCare Pharmaceuticals Inc. | $5,489 | 5 | $0 (2020) |
| Blue Earth Diagnostics Limited | $1,500 | 1 | $0 (2021) |
| GE HEALTHCARE | $539.90 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $238.97 | 2 | $0 (2024) |
| Eli Lilly and Company | $53.56 | 1 | $0 (2024) |
| Lantheus Medical Imaging, Inc. | $26.86 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,849 | 13 | Y-mAbs Therapeutics, Inc. ($4,440) |
| 2023 | $6,659 | 12 | Y-mAbs Therapeutics, Inc. ($6,420) |
| 2022 | $10,985 | 6 | Y-mAbs Therapeutics, Inc. ($6,538) |
| 2021 | $8,198 | 3 | Siemens Medical Solutions USA, Inc. ($6,698) |
| 2020 | $13,296 | 5 | Ipsen Bioscience Inc ($8,000) |
| 2019 | $25,788 | 16 | Progenics Pharmaceuticals, Inc. ($17,755) |
| 2018 | $13,063 | 13 | Siemens Medical Solutions USA, Inc. ($13,036) |
| 2017 | $627.11 | 5 | GE HEALTHCARE ($539.90) |
All Payment Transactions
73 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/21/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $53.56 | General |
| 09/05/2024 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 06/10/2024 | Siemens Medical Solutions USA, Inc. | Biograph Vision 600 (8 Ring/64 CT) (Device) | Food and Beverage | In-kind items and services | $121.16 | General |
| Category: MI - Nuclear Medicine (incl. PETNET & MIBR) | ||||||
| 05/26/2024 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $1,440.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 05/25/2024 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $180.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 05/24/2024 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $180.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 05/23/2024 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $180.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 05/22/2024 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $540.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 05/21/2024 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $180.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 05/20/2024 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $420.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 05/16/2024 | Siemens Medical Solutions USA, Inc. | Biograph Vision 600 (8 Ring/64 CT) (Device), Cerianna | Food and Beverage | In-kind items and services | $83.38 | General |
| Category: MI - Nuclear Medicine (incl. PETNET & MIBR) | ||||||
| 04/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $150.60 | General |
| Category: Oncology | ||||||
| 02/07/2024 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $120.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 11/30/2023 | Siemens Medical Solutions USA, Inc. | Biograph Vision 600 (8 Ring/64 CT) (Device) | Food and Beverage | In-kind items and services | $44.61 | General |
| Category: MI - Nuclear Medicine (incl. PETNET & MIBR) | ||||||
| 11/02/2023 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $660.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 11/02/2023 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $300.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 10/25/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $88.37 | General |
| Category: Oncology | ||||||
| 10/11/2023 | Siemens Medical Solutions USA, Inc. | — | Food and Beverage | In-kind items and services | $94.35 | General |
| 10/11/2023 | Siemens Medical Solutions USA, Inc. | — | Food and Beverage | In-kind items and services | $12.07 | General |
| 02/16/2023 | Y-mAbs Therapeutics, Inc. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | ||||||
| 02/16/2023 | Y-mAbs Therapeutics, Inc. | — | — | Cash or cash equivalent | $60.00 | Research |
| Study: A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | ||||||
| 02/09/2023 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $1,800.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 02/09/2023 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $1,800.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 01/10/2023 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $600.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
| 01/10/2023 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | — | Cash or cash equivalent | $600.00 | Research |
| Study: A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW • Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW | Y-mAbs Therapeutics, Inc. | $16,738 | 18 |
| A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | Y-mAbs Therapeutics, Inc. | $660.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 445 | 460 | $367,047 | $95,713 |
| 2022 | 14 | 704 | 723 | $520,789 | $142,306 |
| 2021 | 13 | 748 | 791 | $646,235 | $180,917 |
| 2020 | 11 | 454 | 474 | $341,082 | $89,979 |
Total Patients
2,351
Total Services
2,448
Medicare Billing
$508,916
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 121 | 126 | $196,662 | $68,360 | 34.8% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2023 | 140 | 145 | $62,538 | $12,840 | 20.5% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 44 | 47 | $55,460 | $4,386 | 7.9% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 12 | 13 | $12,636 | $3,881 | 30.7% |
| 78816 | Nuclear medicine study whole body with ct scan | Facility | 2023 | 26 | 27 | $11,286 | $2,535 | 22.5% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Facility | 2023 | 13 | 13 | $4,229 | $908.25 | 21.5% |
| 78830 | Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | Facility | 2023 | 15 | 15 | $3,450 | $818.99 | 23.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 11 | 11 | $3,443 | $758.89 | 22.0% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Facility | 2023 | 12 | 12 | $1,680 | $391.01 | 23.3% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 20 | 20 | $6,600 | $327.62 | 5.0% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Facility | 2023 | 13 | 13 | $1,287 | $312.13 | 24.3% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 18 | 18 | $7,776 | $194.65 | 2.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 173 | 182 | $253,290 | $89,966 | 35.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2022 | 211 | 215 | $87,720 | $19,407 | 22.1% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2022 | 30 | 31 | $34,564 | $11,165 | 32.3% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 60 | 62 | $73,160 | $5,684 | 7.8% |
| 78608 | Nuclear medicine study of brain with metabolic evaluation | Office | 2022 | 12 | 12 | $13,104 | $4,820 | 36.8% |
| 78816 | Nuclear medicine study whole body with ct scan | Facility | 2022 | 42 | 44 | $18,392 | $4,000 | 21.8% |
| 78830 | Nuclear medicine study, 1 area with spect and concurrent ct scan | Facility | 2022 | 20 | 20 | $4,600 | $1,143 | 24.8% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Facility | 2022 | 31 | 32 | $4,480 | $1,084 | 24.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 15 | 15 | $4,765 | $987.89 | 20.7% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2022 | 13 | 13 | $3,172 | $838.98 | 26.4% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Facility | 2022 | 11 | 11 | $3,223 | $804.69 | 25.0% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Office | 2022 | 18 | 18 | $2,520 | $608.44 | 24.1% |
| 78803 | Nuclear medicine study, 1 area with spect | Facility | 2022 | 14 | 14 | $2,464 | $548.81 | 22.3% |
About Dr. Daniel Pryma, MD
Dr. Daniel Pryma, MD is a Specialist healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1366417818.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Pryma, MD has received a total of $83,465 in payments from pharmaceutical and medical device companies, with $4,849 received in 2024. These payments were reported across 73 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($32,370).
As a Medicare-enrolled provider, Pryma has provided services to 2,351 Medicare beneficiaries, totaling 2,448 services with total Medicare billing of $508,916. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Nuclear Medicine
- Location Philadelphia, PA
- Active Since 02/20/2006
- Last Updated 05/21/2012
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1366417818
Products in Payments
- Biograph Horizon (Device) $10,511
- DANYELZA (Drug) $10,200
- Biograph Vision (Device) $7,849
- Cerianna (Drug) $6,698
- Xofigo (Drug) $5,489
- AZEDRA (Drug) $4,340
- Axumin (Drug) $1,500
- Biograph Vision 600 (8 Ring/64 CT) (Device) $357.02
- KISQALI (Drug) $150.60
- Biograph mCT (Device) $112.19
- Symbia.net (Device) $101.16
- PLUVICTO (Drug) $88.37
- Biograph mCT Flow (Device) $48.68
- Technelite (Drug) $26.86
- Biograph eco (Device) $23.53
- LUTATHERA (lutetium Lu 177 dotatate) (Drug) $15.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Philadelphia
Hossein Borghaei, M.d, M.D
Specialist — Payments: $673,498
Specialist $673,498
Lori Goldstein, M.d, M.D
Specialist — Payments: $172,547
Specialist $172,547
Dr. Phillip Ginsberg, D.o, D.O
Specialist — Payments: $135,934
Specialist $135,934
Dr. Michael Metro, M.d, M.D
Specialist — Payments: $125,377
Specialist $125,377
Dr. Russell Schilder, M.d, M.D
Specialist — Payments: $124,479
Specialist $124,479
Richard Bleicher, Md, MD
Specialist — Payments: $53,374
Specialist $53,374